SAB-142 shows favorable safety and pharmacodynamic activity in Phase 1 trial, advancing to Phase 2b for type 1 diabetes. SAB BIO announced positive results from its Phase 1 trial of SAB-142, a novel ...
SAB BIO to Host Webinar Discussing Topline Results from Phase 1 Trial of SAB-142 for Type 1 Diabetes
SAB BIO will host a webinar on January 28, 2025, to discuss Phase 1 trial data for its T1D therapy, SAB-142. SAB BIO, a clinical-stage biopharmaceutical company, announced it will host a webinar on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback